Purpose. Special considerations in the selection of medication inhaler devices for elderly patients with chronic obstructive pulmonary disease (COPD) in the ambulatory care setting are reviewed.

Hydroxychloroquine is under clinical development by PureIMS and currently in Phase I for Coronavirus Disease 2019 (COVID-19).

A device costing just pennies, based on an idea by a University of Manchester Professor to help his son use an inhaler, could ...

GSK has developed a new propellant technology for inhaler devices that drastically reduces their use of greenhouse gases, which perhaps surprisingly account for nearly half (49%) of the group’s ...

A device costing just pennies, based on an idea by a University of Manchester Professor to help his son use an inhaler, could be a gamechanger for asthma patients. The impressive results are from ...

Like many parents of asthmatic children, Tariq Aslam found it incredibly difficult to watch his young son struggling to cope ...

The deep penetration of digital systems into the inhaler market has been advantageous in terms of ruling out several device and design errors. The implementation of microprocessors in inhalers for ...

On December 20, 2024, the US Court of Appeals for the Federal Circuit released its opinion in Teva Branded Pharm. Prods. R&D, Inc. v. Amneal ...

Teva has launched a digitally-enabled inhaler in the UK, the first European market for the device, for use by patients with asthma and chronic obstructive pulmonary disorder (COPD). The GoResp ...

The Dry Powder Inhaler Market is poised for significant growth, with a market value of USD 20.83 billion in 2024, projected to climb to USD 29.95 billion by 2034, representing a steady CAGR of 3. ...

Vectura Group Limited is a British pharmaceuticals company based in Chippenham, England, which develops inhaled medicines and ...